CRP and cardiovascular disorder: Although HCQ is a disease-modifying drug in treatment of RA, the effect of HCQ on inflammation in terms of ESR, CRP and swollen joints is modest, and not of the magnitude to make reduction of systemic inflammation per se a reasonable explanation to the impact of HCQ on cardiovascular disease in patients with RA [31].